Maxim Group Analysts Give Cytosorbents (CTSO) a $12.00 Price Target

Maxim Group set a $12.00 price objective on Cytosorbents (NASDAQ:CTSO) in a report published on Monday. The firm currently has a buy rating on the medical research company’s stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright restated a buy rating and set a $13.00 price target on shares of Cytosorbents in a report on Tuesday, September 26th. B. Riley restated a buy rating and set a $11.25 price target on shares of Cytosorbents in a report on Friday, November 10th. Finally, ValuEngine cut shares of Cytosorbents from a hold rating to a sell rating in a report on Friday, December 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $10.60.

Cytosorbents (CTSO) traded down $0.10 during trading on Monday, reaching $7.40. 245,028 shares of the company traded hands, compared to its average volume of 173,917. Cytosorbents has a 1-year low of $3.30 and a 1-year high of $7.55. The stock has a market capitalization of $212.32, a PE ratio of -19.47 and a beta of -0.54. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73.

In other Cytosorbents news, COO Vincent Capponi sold 4,000 shares of Cytosorbents stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the chief operating officer now owns 271,062 shares of the company’s stock, valued at $1,897,434. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Fortaleza Asset Management Inc. raised its position in Cytosorbents by 81.6% in the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after acquiring an additional 10,500 shares during the period. PNC Financial Services Group Inc. raised its position in Cytosorbents by 145.2% in the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after acquiring an additional 22,500 shares during the period. Finally, Wealthcare Advisory Partners LLC bought a new stake in Cytosorbents in the third quarter worth about $365,000. 8.65% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.themarketsdaily.com/2018/01/10/maxim-group-analysts-give-cytosorbents-ctso-a-12-00-price-target-2.html.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply